Psychedelics and Psychedelic-Assisted Psychotherapy
The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Objective: The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. Methods: Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on “psilocybin,” “lysergic acid diethylamide,” “LSD,” “ayahuasca,” “3,4-methylenedioxymethamphetamine,” and “MDMA,” in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and screened. Articles that did not contain the terms “clinical trial,” “therapy,” or “imaging” in the title or abstract were filtered out. The 161 remaining articles were reviewed by two or more authors. The authors identified 14 articles reporting on well-designed clinical trials investigating the efficacy of lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ayahuasca for the treatment of mood and anxiety disorders, trauma and stress-related disorders, and substance-related and addictive disorders as well as in end-of-life care. Results: The most significant database exists for MDMA and psilocybin, which have been designated by the U.S. Food and Drug Administration (FDA) as “breakthrough therapies” for posttraumatic stress disorder (PTSD) and treatment-resistant depression, respectively. The research on LSD and ayahuasca is observational, but available evidence suggests that these agents may have therapeutic effects in specific psychiatric disorders. Conclusions: Randomized clinical trials support the efficacy of MDMA in the treatment of PTSD and psilocybin in the treatment of depression and cancer-related anxiety. The research to support the use of LSD and ayahuasca in the treatment of psychiatric disorders is preliminary, although promising. Overall, the database is insufficient for FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders at this time, but continued research on the efficacy of psychedelics for the treatment of psychiatric disorders is warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, comorbid conditions such as suicidality and substance use disorders further complicate research efforts (13, 18, 20, 21).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [21]
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Reiff et al., 2020
In the citing paper
“Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are also novel therapeutics for MDD that show promise in clinical trials [124-126].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [126]
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Ketamine NMDA antagonist Deficits in vigilance, verbal fluency, delayed recall, and tests of frontal lobe function (121) Derealization, depersonalization (8, 120, 121, 124); illusions in all sensory domains and perceptual alterations (121) Amotivation, emotional dulling, hostility (121); anxiety (121, 123) Improved mo…”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Journal of Transpersonal Psychology
(1977) · Journal of Humanistic Psychology · doi:10.1177/002216787701700308 · Cited by 1,732
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 4×
“The mean change in HAM-D score 21 days after drug administration was 211.4. a AASE=Alcohol Abstinence Self-Efficacy Scale; BDI=Beck Depression Inventory; CAPS=Clinician-Administered PTSD Scale; LSD=lysergic acid diethylamide; DMT=N,N-dimethyltryptamine; HADS=Hospital Anxiety and Depression Scale; HAM-A=Hamilton Anxiet…”
BackgroundMethodInfluentialDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 3×
“(23) conducted an openlabel pilot study evaluating the feasibility and efficacy of”
BackgroundCarhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Research works printed but not linked: 13
- Lee M, 1992, Acid Dreams: The Complete History of LSD: The CIA, The Sixties, and Beyond
- Darling DC, 2006, Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom
- Pahnke WN, 1969, Int Psychiatry Clin, 5, 149
- Abramson HA: The Use of LSD in Psychotherapy, in Transactions of a Conference on d-Lysergic Acid Diethylamine (LSD-25). New York: Josiah Macy Jr. Foundation Publications, 1959
- Grof S, 1977, The Human Encounter With Death
- Labate BC, 2009, Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays
- Holland J, 2001, Ecstasy: The Complete Guide
- Mithoefer MC, 2013, A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder
- Grof S, 2008, LSD Psychotherapy
- Kalant H, 2001, CMAJ, 165, 917
- Preller KH, 2018, Behavioral Neurobiology of Psychedelic Drugs, 221
- Aarde SM, 2017, Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines, 145
- Heifets BD, JAMA Psychiatry
Cited by
Items 601–647 of 647
Cordahi, C. C., Richa, S., Durrani, B., Dagher, R., Johnson, R. A., Safieddine, M., Anouti, S., Ravez, L., Choucair, N., Kazaal, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9051053/v1
Psychedelic-assisted therapy for death acceptance in terminal illness: A scoping review
Whitmore, H., Anderson, B. T., Flowers, E., Penn, A., & Leutwyler, H. C. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00474
Raihan, A. (2026) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2026.100571
Khosravi, M., Berardis, D. D., & Tusconi, M. (2026) · Mental Wellness · doi:10.4081/mw.2026.40
Low, Z. X. B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111717 · Cited by 2
Cluck, M., Purcell, A. B., Kazan, Z., Robinson, J. O., McGuire, A. L., & Neitzke‐Spruill, L. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100020
Psychedelic Use and Psychological Healing Among Gender Exploring Clients: Clinicians’ Perspectives
Cassidy, E. K., Riccardi, J., Healy, B., Golakoti, S. S. M., & Farvid, P. (2026) · Women & Therapy · doi:10.1080/02703149.2026.2667141 · Cited by 1
“Our study is situated within the third wave of psychedelic research, which emphasizes the integration of psychedelic substances within professional mental health care framework (George et al., 2022; Reiff et al., 2020).”
Simon, G., Tadmor, N., Evans, J., Luke, D. P., & Luoma, J. B. (2026) · Research Square · doi:10.21203/rs.3.rs-9695196/v1 · Cited by 1
Marsh, D. A., & Bacalso, E. (2026) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-026-00384-1
“However, there has been a resurgence of interest in their therapeutic benefits as researchers build evidence for their safety and efficacy [ 17].”
Ayahuasca use and improvements in suicidal behavior: An exploratory qualitative study
Santos, N. V. M., Silveira, C. F., Costa, C. G. D. S. S., Basso, H. P., Barbosa, P. C. R., & Morais, P. R. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100023
Psychedelics and neurostimulation for treatment resistant psychiatric disorders
Blažek, F., Látalová, K., Krahulík, D., & Hrabálek, L. (2026) · Discover Mental Health · doi:10.1007/s44192-026-00486-5
“Regulatory agencies have shown increasing receptivity to reevaluating psychedelic and neuromodulatory treatments, as evidenced by the FDA granting “breakthrough therapy” status for psilocybin in treating depression [15].”
Influential(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551944.bm01
Pines, A. R., Zhang, X., Kochalka, J., Vesuna, S. S., Kauvar, I., Rajasekharan, D., Reneau, T. R., Akiki, T. J., Hack, L. M., Siegel, J. S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2522000123 · Cited by 4
Guimarães, A. L., Beserra, F. R., da Cruz, L. V. M., Bienemann, B., FREIND, J. M. K., Guinle, V., Rodrigues, R., Regalado, J. A., & Mograbi, D. C. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.05.012 · Cited by 1
Labra-Lorenzana, A., Lima-Sánchez, D. N., Delaflor-Wagner, C. A., Martínez-Hernández, D. G., Ramos-Jiménez, C., & Toledo-Lozano, C. G. (2026) · Psychiatry International · doi:10.3390/psychiatryint7030137
Frick, A., Blest‐Hopley, G., Grin, M., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2026) · Psychopharmacology · doi:10.21203/rs.3.rs-9880403/v1
Brar, P. S., Price, R. B., Ross, S., Tofighi, B., & Sarpal, D. K. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456191
“However, the presence of psychosis or a schizophrenia spectrum disorder (SSD) is, categorically, a strict contraindication in recent studies examining psychedelic drugs as therapeutic agents (Johnson et al., 2008; Nutt and Carhart-Harris, 2021; Reiff et al., 2020).”
The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review
Ferreira, F. G. D. P., Fernandes, J. A. B., Filev, R., da Silveira, D. X., & Fidalgo, T. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453850
Schuman, H. D. M., Mina, R., Barkova, S., Nguyen, T., Deleemans, J. M., & Carlson, L. E. (2026) · Global Advances in Integrative Medicine and Health · doi:10.1177/27536130261459354
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
Hummel, H. M., Obrochta, A. N., Kerr, D. C. R., & Cservenka, A. (2026) · Journal of Drug Issues · doi:10.1177/00220426261466154
Psychedelics, rebirth experiences, and the limits of current research
Artru, E. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100028
Dissociation and antidepressant response to subcutaneous esketamine: A clinical study
Gonçalves, K. T. D. C., Tavares, V. D. D. O., Palhano-Fontes, F., Cavalcanti-Ribeiro, P., de Almeida, V. R. N., Barbosa, D. C., Fernandes, T. U. G., Cardoso, E. I. T., Lima, N. B. D. M., de Brito, A. J. C., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.07.016
Cardiovascular safety of psilocybin in psychiatric practice: a narrative review
Szarpak, Ł., Pruc, M., Świeczkowski, D., Rybczynski, B., Pięta, A., & Cubała, W. J. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04151-2
Kerr, K., Anderson, T., Blackman, G., Copping, A., Detert, N., Garfield, A., Gilli, P., Goldstein, L. H., Green, H., Harrison, S., et al. (2026) · Journal of Neuropsychology · doi:10.1111/jnp.70070
Bhagavan, C., Carter, O. L., Nielsen, G., Berlowitz, D. J., Issak, S., Braat, S., Zaloumis, S. G., Attard, Z., Oliver, G., Mayne, D., et al. (2026) · CNS Drugs · doi:10.1007/s40263-026-01326-4 · Cited by 2
“Therefore, low-to-moderate doses of psilocybin were selected to enable movement task exploration below the 25 mg dose commonly used in psychedelic-assisted psychotherapy trials where physical activity is often limited [14–16].”
Pack, S., Ellett, T. R., PHAM, J., & Ahmad, Y. (2026) · Cureus · doi:10.7759/cureus.114211
“DMT itself acts as an agonist at serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, as well as a serotonin transporter and norepinephrine transporter inhibitor [5].”
InfluentialThe Australian Ayahuasca Dietero Networks: Culture, Community, and Practices
Roy, A., Williams, M. L., Day, K., & Barratt, M. J. (2026) · Contemporary Drug Problems · doi:10.1177/00914509261473569
Singh, A. N. A., Cook, K., & Hill, B. D. (2026) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-026-00393-0
Cahill, J. D., & Gallagher, K. (2026) · Cambridge University Press eBooks · doi:10.1017/9781108689229.010
Psychologists’ attitudes towards the use of MDMA in therapy may be shaped by personal experiences
Csákó, R. I., Shepherd, D., Vitális, E. ́., & Cullen, D. (2026) · Clinical Psychologist · doi:10.1080/13284207.2026.2703685
Prescribers in the Era of Neuroscience
Miller, C. W. T., & Kvarta, M. D. (2026) · Cambridge University Press eBooks · doi:10.1017/9781108689229.031
Salvinorin A in humans: A systematic review of pharmacokinetics, pharmacodynamics, and safety
Zürrer, W. E., Liesner, J., Brüschweiler, D., Aicher, H., Scheidegger, M., & Ineichen, B. V. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473385
Mele, M. L., & Federici, S. (2026) · Springer eBooks · doi:10.1007/978-981-92-1629-1_201-1
Psilocybin-Assisted Therapy for Alcohol Use Disorder: A Systematic Review of Clinical Evidence
Schäffert, L., & Unterrainer, . (2026) · Psychoactives · doi:10.3390/psychoactives5030022
Psilocibina e neuroplasticidade: novas perspectivas terapêuticas para depressão resistente
Castro, L. A., Júnior, A. L. A. S., Simões, G. G. C., de Souza, V. R. S., Pereira, L. L. M. D., Lacerda, A. L. D. S., & da Silva, C. L. (2026) · Vértices · doi:10.19180/1809-2667.v28n22026.23658
Fletcher, K., Freestone, J., Ezard, N., Knock, E., & Siefried, K. J. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00783-7
Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis
Świeczkowski, D., Kwaśny, A., & Cubała, W. J. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2727030
Psychedelics in the Future of Global Mental Healthcare
Aleksandrova, L. R., Thiessen, K. A., Chen, F. X. F., Phillips, A. G., Schütz, C. G., & Krausz, M. (2026) · Springer eBooks · doi:10.1007/978-3-319-70134-9_174-1
Lueken, U., Dziobek, I., Havenith, M. N., Schild, M., & Daedelow, L. S. (2026) · npj Mental Health Research · doi:10.1038/s44184-026-00246-x
“…effects (e.g., emotional breakthrough, insight, catharsis 3,9 ) that parallel the acute effects underlying pharmacologically-induced psychedelic therapies with serotonergic psychedelics 11,14,15 - but with comparably lower legal and regulatory hurdles and a more bene fi cial safety pro fi le.”
Group psychedelic-assisted therapy for mental health conditions: a mixed-methods systematic review
Tsang, V. W. L., Bhatia, F., Ferrey, A. E., & Hartmann‐Boyce, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1788352
“This is especially considered when other methods have failed to achieve remission (2).”
Cubała, W. J. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2744754
How ‘people power’ and business transformed medicine, but created a whole new set of risks
Hallinan, C. (2026) · The Conversation · doi:10.64628/aa.mnacny9sa
Rouleau, R., Oubraim, S., Cirone, L., Shen, R., & Haj‐Dahmane, S. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1951375
“Importantly, the hallucinogenic effects of serotonergic psychedelics are mediated, at least in part, through alterations in CLA function (Barrett et al., 2020; Doss et al., 2022; Reiff et al., 2020).”
The Serenity Spectrum: Integrating Anxiolytic and Antidepressant Mechanisms for Stress relief
Harini., M. B., & Verma, P. (2026) · Asian Journal of Research in Pharmaceutical Sciences · doi:10.52711/2231-5659.2026.00063
Szarpak, Ł., Pruc, M., Jablonska-Moczulo, D., Niewiadomska, I., Rybczynski, B., & Cubała, W. J. (2026) · Therapeutics · doi:10.3390/therapeutics3040021
AbouEich, H. K., Izadi, A., Lifshitz, J., Olson, D. E., & Gurkoff, G. G. (2026) · Journal of Neurotrauma · doi:10.1177/08977151261495030
Metadata
- Authors
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R.
- Affiliations
- Emory University (US)
- Department of Psychiatry, New York University School of Medicine, New York (Reiff); Department of Psychiatry and Human Behavior, Emory University School of Medicine, Atlanta (Richman, McDonald); Department of Psychiatry, Dell Medical School and the Institute for Early Life Adversity Research, University of Texas at Austin (Nemeroff); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, R.I. (Carpenter); Department of Psychiatry and Behavioral Sciences, University of...
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2020-05-01
- Volume
- 177
- Issue
- 5
- Pages
- 391-410
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3006905788
- Cited by
- 649
- References
- 120
- Citations by year
- 2026: 93 · 2025: 126 · 2024: 129 · 2023: 113 · 2022: 102 · 2021: 60 · 2020: 26
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG059307)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelics, psychedelic-assisted psychotherapy, psilocybin, LSD, ayahuasca, MDMA, post-traumatic stress disorder, treatment-resistant depression, cancer-related anxiety, substance use disorders, trauma and stress-related disorders, end-of-life care
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Lysergic Acid Diethylamide, Psilocybin, Psychotherapy, N-Methyl-3,4-methylenedioxyamphetamine, Evidence-Based Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.